NextCell Pharma AB publishes its interim report for September 2019 - May 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - May 31, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reportNine months (2019-09-01 until 2020-05-31) · Operating income amounted to SEK 3 191 314 (1 273 201). · Operating result amounted to SEK -12 803 349 (-13 477 202). · Earnings per share* amounted to SEK -1,11 (-1,17). · Cash and bank amounted to SEK 5 612 952 (2 249 092). In addition, after the end of the period, in June 2020, the Company received an